Novo Nordisk, a Danish pharmaceutical giant, has sought legal intervention in South Africa to halt the distribution of unauthorized versions of its semaglutide-based drugs for weight loss and diabetes. The company has filed an application in the South African High Court against iDexis, a local compounding pharmacy accused of making and selling these products without regulatory approval.<\/p>\n
The core of the case lies in patient safety, product integrity, and regulatory compliance. Compounding, which involves customizing medication for individual patients, is heavily regulated in South Africa, prohibiting large-scale production of unregistered drugs. The dispute centers on iDexis’s version of semaglutide and whether it matches the approved formulation used by Novo Nordisk.<\/p>\n
This South African lawsuit echoes Novo Nordisk’s similar battles elsewhere, including in the United States, to curb the unauthorized sale of GLP-1 drugs. These products have gained popularity due to their efficacy in diabetes management and weight loss, creating a grey market due to high demand and pricing challenges.<\/p>\n
(With inputs from agencies.)<\/p>\n","protected":false},"excerpt":{"rendered":"Novo Nordisk, a Danish pharmaceutical giant, has sought legal intervention in South Africa to halt the distribution of…\n","protected":false},"author":2,"featured_media":104723,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[15786,3335,53308,20191,272,21306,689,17938,9167,280],"class_list":["post-104722","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-diabetes","tag-glp-1","tag-idexis","tag-legal-battle","tag-novo-nordisk","tag-pharmaceutical","tag-semaglutide","tag-south-africa","tag-unapproved-drugs","tag-weight-loss"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116726559095327186","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/104722","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=104722"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/104722\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/104723"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=104722"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=104722"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=104722"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}